var pausecontent=new Array()
//pausecontent[0]='<b><i>February 2009</i></b><p class="smtextblack">We are proud to announce that a sponsored observational study has been successful coming to recruit 690 subjects, 40 more than the defined objective, in about 65 centres. This has been obtained after one year from contract signature. This success is related to our IRB department, Project Management and new effective Recruitment Procedure</p>'
//pausecontent[1]='<b><i>December 2008</i></b><p class="smtextblack">Sponsored clinical trial PROTECHT with 62 centers in Italy enrolled 1166 patients and randomized them to get placebo or the low-molecular weight heparin nadroparin (Fraxiparine) for the duration of their chemotherapy. The researchers found that the rate of clinical thrombosis among the placebo group was 3.9%, compared with only 2% among those getting the blood-thinner. That yielded a relative risk reduction of 49.6%, which was significant at P=0.024. (continues...)</p></p>'
//pausecontent[0]='<b><i>December 2009</i></b><p class="smtextblack">Dear All, we are pleased to inform you that effective December 16th, 2009 Hyperphar Group SpA will change its company name into PIERREL RESEARCH ITALI SpA. Concomitantly the new e.mail address will be: first name initial.surname@pierrelgroup.com (e.g. m.rossi@pierrelgroup.com). All other company business details will remain unchanged (i.e. VAT code, fiscal identification code and Registry of Commerce number, telephone and fax numbers, address of registered and operational offices).</p>'
// as well as the present operative organization.</p>'
pausecontent[0]='<div style="text-align:right;"><b><i>October 2009</i></b></div><div style="margin-top:5px;">Pierrel Research Italy is proud to annunce the GIOTTO project has gained the single opinion approval within 3 weeks from submission</div>'
pausecontent[1]='<div style="text-align:right;"><b><i>July 2009</i></b></div><div style="margin-top:5px;">Pierrel Research Italy is proud to annunce that the Pulmonary Embolism International Thrombolysis Trial (PEITHO)  enrolled its 258th patient last weekend, which means that this joint European effort is already the largest randomised thrombolytic trial EVER performed in acute pulmonary embolism. An interim analysis was performed at 250 patients as planned, and the study data also were reviewed by the Data Safety Monitoring Board</div>'
//pausecontent[5]='<b>July 2008</b><p class="smtextblack">Piergiorgio Galletti MD, has recently joined Hyperphar, as Director Clinical Operations. He has been working in the field of clinical research for more than 20 years, performing his professional career in major International Pharmaceutical Companies and CRO.Piergiorgio Galletti MD, has recently joined Hyperphar, as Director Clinical Operations. He has been working in the field of clinical research for more than 20 years, performing his professional career in major International Pharmaceutical Companies and CRO.Piergiorgio Galletti MD, has recently joined Hyperphar, as Director Clinical Operations. He has been working in the field of clinical research for more than 20 years, performing his professional career in major International Pharmaceutical Companies and CRO.Piergiorgio Galletti MD, has recently joined Hyperphar, as Director Clinical Operations. He has been working in the field of clinical research for more than 20 years, performing his professional career in major International Pharmaceutical Companies and CRO.Piergiorgio Galletti MD, has recently joined Hyperphar, as Director Clinical Operations. He has been working in the field of clinical research for more than 20 years, performing his professional career in major International Pharmaceutical Companies and CRO.</p>'